What patents cover avibactam, and who owns them?
Avibactam is a beta-lactamase inhibitor used in combination antibiotics. Patents for avibactam are typically held by the company that developed it and by organizations that file around specific uses, formulations, manufacturing processes, or particular combination regimens (for example, pairing with a companion antibiotic). Which exact patents apply depends on the country/jurisdiction and whether you are looking for the original molecule coverage, a combination-use claim, or later-life-cycle improvements (formulations, salts, dosing regimens, etc.).
When do avibactam-related patents expire?
Patent expiry dates depend on:
- the filing date of each specific patent family,
- the jurisdiction (US, EP, UK, etc. can differ),
- whether patent term adjustments or extensions apply, and
- whether regulators granted any exclusivity that affects market entry beyond the base patent term.
Because expiry is patent-by-patent, you generally need to identify the exact patent numbers in the relevant jurisdictions before you can state a date.
Can generic or biosimilar versions of avibactam enter before the “main” patent expires?
Often, generic manufacture and marketing of an active ingredient can become possible only when both:
- composition/active-ingredient patents (if any) expire or are non-infringing, and
- combination/regimen or method-of-treatment patents that cover the approved drug product are no longer enforceable (or can be designed around).
If a combination product is covered by additional patents beyond the underlying inhibitor molecule, that can delay entry even after some earlier patents lapse.
Are there patent challenges or “workaround” strategies?
Where patents cover avibactam combinations, the typical workaround strategies are legal/technical rather than clinical changes:
- challenging validity or enforceability,
- arguing non-infringement (e.g., different formulation, dosing, or claim scope),
- waiting for the relevant claims to expire, or
- targeting a different combination approach that falls outside protected claims.
Whether any specific challenges exist for avibactam in a given country can only be confirmed by checking litigation and patent registers there.
How do you find the right avibactam patents for a specific product or country?
To get accurate answers (such as exact expiry dates), you usually start from:
- the approved product label and its manufacturer(s),
- the active ingredient and companion antibiotic used with avibactam,
- the patent landscape tools or official registers for the target jurisdiction (e.g., national patent databases and patent term extension registers),
- the list of patents linked to the product (where available), and
- the patent family identifiers (to track filings across countries).
If you tell me the jurisdiction (US/EU/UK/etc.) and which avibactam product you mean (the companion antibiotic matters), I can narrow down what patents and expiration windows to look for.
What information do you need to identify specific “avibactam patents”?
To avoid mixing up different patent families, it helps to know:
- the companion antibiotic (e.g., which approved combo),
- the country you care about,
- whether you mean molecule patents, combination patents, or process/formulation patents,
- whether you want the “last-to-expire” patent (often the most relevant for market entry).
Sources
No sources were provided in the prompt, so I cannot cite specific avibactam patent documents or dates.